SCN8A Developmental and Epileptic Encephalopathy Syndrome
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Neurocrine BiosciencesSAN DIEGO, CA
2 programs2
NBI-921352Phase 21 trial
NBI-921352Phase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
Neurocrine BiosciencesNBI-921352
Neurocrine BiosciencesNBI-921352
Clinical Trials (2)
Total enrollment: 16 patients across 2 trials
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Start: Jul 2022Est. completion: Mar 20268 patients
Phase 2Active Not Recruiting
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Start: Jan 2022Est. completion: Mar 20238 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.